| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| B M Arafah, K E Nekl, R S Gold, W R Selma. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. The Journal of clinical endocrinology and metabolism. vol 80. issue 12. 1996-01-31. PMID:8530591. |
the mild increase in serum prl levels in hypopituitary patients and the discordant responses to stimulation with trh and pz suggest dopamine deficiency as a cause of hyperprolactinemia. |
1996-01-31 |
2023-08-12 |
Not clear |
| M Knoepfelmacher, S M Villares, W Nicolau, O O Germek, A C Lerário, B L Wajchenberg, B Liberma. Calcium and prolactin secretion in humans: effects of the channel blocker, verapamil, in the spontaneous and drug-induced hyperprolactinemia. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 26. issue 10. 1995-03-10. PMID:7851873. |
the authors discuss the possibility that the divergent effects of verapamil in hyperprolactinemia of different etiologies could be related to the balance between dopamine and calcium channel effects on hypothalamus and/or pituitary. |
1995-03-10 |
2023-08-12 |
human |
| B Merola, F Sarnacchiaro, A Colao, C Di Somma, A Di Sarno, D Ferone, A Selleri, M L Landi, G Schettini, C Napp. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. vol 8. issue 3. 1995-03-07. PMID:7847102. |
the clinical effects of cv 205-502, a potent and non-ergot-derived dopamine agonist, were investigated in 24 selected patients with hyperprolactinemia previously treated with standard oral bromocriptine, the slow-release oral form of bromocriptine (brc-sro) and/or the long-acting injectable form of bromocriptine (brc-lar); 14 were chosen because of their resistance to treatment and ten because they were intolerant of the different forms of bromocriptine. |
1995-03-07 |
2023-08-12 |
Not clear |
| B Merola, F Sarnacchiaro, A Colao, C Di Somma, A Di Sarno, M L Landi, P Marzullo, N Panza, C Battista, G Lombard. CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 48. issue 3-4. 1995-01-18. PMID:7993981. |
cv 205-502 (octahydrobenzol[g]quinoline), a non-ergot dopamine agonist drug, was administered to 40 patients with hyperprolactinemic syndrome: 16 patients with macroprolactinoma, 14 with microprolactinoma and 10 with non-tumoral hyperprolactinemia. |
1995-01-18 |
2023-08-12 |
Not clear |
| F V Shikaeva, N F Efimenk. [Hormonal-mediator interrelationships in polycystic ovary syndrome]. Problemy endokrinologii. vol 40. issue 4. 1994-12-22. PMID:7971905. |
examinations of 33 patients with the polycystic ovaries syndrome with measurements of monoamines, ovarian and gonadotropic hormones, and prolactin revealed disordered monoaminergic regulation in all the patients, manifesting by reduced dopamine level in normoprolactinemia and its reduction parallelled by increase of serotonin level in hyperprolactinemia. |
1994-12-22 |
2023-08-12 |
Not clear |
| M Giusti, E Porcella, A Carraro, M Cuttica, S Valenti, G Giordan. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. Journal of endocrinological investigation. vol 17. issue 1. 1994-07-21. PMID:7911813. |
cabergoline and quinagolide, two new dopamine agonist drugs with long-lasting activity, are currently under investigation for the treatment of hyperprolactinemia. |
1994-07-21 |
2023-08-12 |
Not clear |
| T Mizokawa, T Akai, Y Nakada, M Yamaguchi, H Nakagawa, S Hasan, K J Rettig, H Wachte. Terguride as a new anti-hyperprolactinemic agent: characterization in rats and dogs in comparison with bromocriptine. Japanese journal of pharmacology. vol 63. issue 3. 1994-03-23. PMID:7906316. |
these results suggest that terguride as a dopamine d2-agonist is a potent inhibitor of prl secretion with less neurotropic side effects compared to bromocriptine, and thus a useful drug for the treatment of galactorrhea and hyperprolactinemia including prolactinoma. |
1994-03-23 |
2023-08-12 |
rat |
| S P Chang, H T Ng, T L Lan, H T Chao, T C Wei, T S Yang, X R Ou-Yan. Transient hyperprolactinemia in gonadotropin-stimulated cycles for in vitro fertilization and its effect on conception. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed. vol 51. issue 6. 1994-02-16. PMID:8281485. |
these results do not support the treatment of transient hyperprolactinemia with dopamine agonists in ivf patients. |
1994-02-16 |
2023-08-12 |
human |
| H Pisarek, H Stepien, M Pawlikowsk. Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol-induced hyperplasia of the rat anterior pituitary. Endocrine regulations. vol 26. issue 1. 1992-12-18. PMID:1421203. |
since no data are yet available on the effects of mesulergine on pituitary dopamine receptors, the present study has been designated to elucidate the influence of this drug on prolactin secretion in vivo and in vitro and 3h-spiperone binding by the anterior pituitary gland in female wistar rats with experimentally induced hyperprolactinemia. |
1992-12-18 |
2023-08-11 |
rat |
| T J Kamal, M E Molitc. Effects of calcium channel blockade with verapamil on the prolactin responses to TRH, L-dopa, and bromocriptine. The American journal of the medical sciences. vol 304. issue 5. 1992-12-04. PMID:1332473. |
to determine the mechanisms by which calcium channel blockade with verapamil causes hyperprolactinemia, the authors investigated the effects of this blockade on the prolactin (prl) responses to stimulation by thyrotropin releasing hormone (trh) and inhibition by dopamine, using l-dopa and bromocriptine. |
1992-12-04 |
2023-08-11 |
human |
| C Scavone, R DeLucia, L F Dos-Santo. Hyperprolactinemia induced by long-term domperidone treatment does not alter the sensitivity of striatal dopamine receptors. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. vol 24. issue 6. 1992-09-22. PMID:1823276. |
hyperprolactinemia induced by long-term domperidone treatment does not alter the sensitivity of striatal dopamine receptors. |
1992-09-22 |
2023-08-11 |
rat |
| C Scavone, R DeLucia, L F Dos-Santo. Hyperprolactinemia induced by long-term domperidone treatment does not alter the sensitivity of striatal dopamine receptors. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. vol 24. issue 6. 1992-09-22. PMID:1823276. |
we investigated the effect of hyperprolactinemia induced by long-term domperidone treatment (10.0 mg/kg, single daily dose, ip) on striatal dopamine (da) receptor sensitivity in male wistar rats weighing 250-300 g (n = 8). |
1992-09-22 |
2023-08-11 |
rat |
| F Veglio, G Pinna, F Rabbia, P Mulatero, L Chianduss. [Primary dexamethasone-suppressible hyperaldosteronism and hyperprolactinemia]. Minerva endocrinologica. vol 17. issue 1. 1992-09-08. PMID:1323053. |
our results showed a lack of dopamine inhibiting aldosterone secretion, despite dopaminergic tone is known to be increased in hyperprolactinemia. |
1992-09-08 |
2023-08-11 |
Not clear |
| U Bürgi, R Seile. [Hypophyseal dysfunction and tumors]. Therapeutische Umschau. Revue therapeutique. vol 49. issue 3. 1992-06-18. PMID:1585268. |
alternative therapies are radiation treatment (in nonoperable patients or when hormone levels are persistently elevated after pituitary surgery) and drug treatment (dopamine agonists in hyperprolactinemia, somatostatin analogues in acromegaly). |
1992-06-18 |
2023-08-11 |
Not clear |
| H R Kranzler, D J Wallingto. Serum prolactin level, craving, and early discharge from treatment in cocaine-dependent patients. The American journal of drug and alcohol abuse. vol 18. issue 2. 1992-05-14. PMID:1314018. |
this lack of intercorrelation argues against the notion that dopamine depletion is an adequate explanation for both craving and hyperprolactinemia following chronic cocaine use. |
1992-05-14 |
2023-08-11 |
Not clear |
| F Larrea, A Escorza, X Valencia, I Méndez, R Schiavon, G Forsbac. Reduced dopaminergic inhibition of thyrotropin release in hyperprolactinemic ovulatory women. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. vol 43. issue 4. 1992-04-16. PMID:1798861. |
central dopaminergic activity was investigated by the administration of the dopamine antagonist domperidone to normal women (n = 7) and women with anovulatory (n = 6) and ovulatory hyperprolactinemia (n = 2). |
1992-04-16 |
2023-08-11 |
human |
| F Larrea, A Escorza, X Valencia, I Méndez, R Schiavon, G Forsbac. Reduced dopaminergic inhibition of thyrotropin release in hyperprolactinemic ovulatory women. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. vol 43. issue 4. 1992-04-16. PMID:1798861. |
anovulatory hyperprolactinemic subjects showed the highest response to domperidone in terms of tsh, whereas normal women and women with ovulatory hyperprolactinemia had similar increments in tsh serum levels after the administration of the dopamine antagonist. |
1992-04-16 |
2023-08-11 |
human |
| M Vĕtr, M Talas, A Sobek, J Charamz. Metoclopramide test in women with PCO syndrome after ovarian wedge resection. Acta Universitatis Palackianae Olomucensis Facultatis Medicae. vol 130. 1992-04-02. PMID:1838876. |
this latent hyperprolactinemia presumably might be normalized by dopamine agonist therapy, resulting in resumption of ovulatory cycles in these women. |
1992-04-02 |
2023-08-11 |
human |
| A Schulz, I Lancranjan, T Schürmeyer, F Schuppert, R D Hesch, A von zur Mühlen, G Braban. Efficacy and tolerability of a long-acting intramuscularly injectable depot preparation of bromocriptine: the results of a double blind study. Journal of endocrinological investigation. vol 14. issue 6. 1992-02-28. PMID:1774443. |
the tolerability and efficacy of a long-acting im applicable form of bromocriptine (parlodel lar) was tested in a double-blind approach in 20 patients with hyperprolactinemia or prolactinoma, 17 of them complaining of persistent side effects on oral treatment with dopamine agonists. |
1992-02-28 |
2023-08-11 |
Not clear |
| B Crottaz, A Uske, M J Reymond, F Rey, R A Siegel, J Brownell, F Gome. CV 205-502 treatment of macroprolactinomas. Journal of endocrinological investigation. vol 14. issue 9. 1992-02-07. PMID:1684803. |
in conclusion, cv 205-502, given once daily, appears to be a safe and effective alternative to other dopamine agonists in the treatment of macroprolactinoma, by reducing hyperprolactinemia and tumor size. |
1992-02-07 |
2023-08-11 |
human |